What is Inovio Pharmaceuticals Inc. (INO) Price Targets?

BEPC Stock
BEPC Stock

Inovio Pharmaceuticals Inc. (NASDAQ:INO) saw a downside of -2.37% to close Monday at $1.65 after subtracting -$0.04 on the day. The 5-day average trading volume is 4,668,900 shares of the company’s common stock. It has gained $1.9395 in the past week and touched a new high 2 times within the past 5 days. An average of 4,975,740 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 5,573,406.

INO’s 1-month performance is 0.61% or $0.1200 on its low of $1.3900 reached on 12/27/22. The company’s shares have touched a 52-week low of $1.38 and high of $4.34, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, INO has achieved 5.77% or $0.0900 and has reached a new high 7 times. However, the current price is down -61.96% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

INO stock investors last saw insider trading activity on Aug 11.Weiner David B. (Director) most recently sold 11,875 shares at $2.66 per share on Aug 11. This transaction cost the insider $31,588. Director, BENITO SIMON X, sold 2,000 shares at a price of $2.25 on Jul 20. Then, on May 16, Director Weiner David B. sold 9,000 shares at a price of $1.95 per share. This transaction amounted to $17,550.

Valuation Metrics

INO stock has a beta of 1.07. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 37.20 while the price-to-book (PB) in the most recent quarter is 1.54.

Inovio Pharmaceuticals Inc.’s quick ratio for the period ended September 29 was 3.70, with the current ratio over the same period at 3.70. As well, the company’s long term debt to equity for the quarter ending September 29 was 0.06, while the total debt to equity was 0.06. The firm’s gross profit as reported stood at $302.99 million against revenue of $1.77 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Inovio Pharmaceuticals Inc.’s cash and short-term investments amounted to $307.02 million against total debt of $32.43 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 24.29% to -$108.5 million, while revenue of -$79.07 million was 27.12% off the previous quarter. Analysts expected INO to announce -$0.3 per share in earnings in its latest quarter, but it posted -$0.15, representing a 50.00% surprise. EBITDA for the quarter stood at more than -$34.91 million. INO stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 125.27 million, with total debt at $32.43 million. Shareholders hold equity totaling $249.49 million.

Let’s look briefly at Inovio Pharmaceuticals Inc. (INO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 44.18% to suggest the stock is trending Neutral, with historical volatility in this time period at 75.10%.

The stock’s 5-day moving average is $1.7300, reflecting a -13.16% or -$0.2500 change from its current price. INO is currently trading -1.20% above its 20-day SMA, -28.88% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -22.90% and SMA200 by-56.00%.

Stochastic %K and %D was 42.41% and 52.85% and the average true range (ATR) pointed at 0.1336. The RSI (14) points at 45.63%, while the 14-day stochastic is at 30.61% with the period’s ATR at 0.1369. The stock’s 9-day MACD Oscillator is pointing at -0.0911 and -0.0238 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Inovio Pharmaceuticals Inc. (NASDAQ: INO), Maxim Group downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for INO stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate INO as a “sell,”, while 4 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.

What is INO’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $2.00 and a high of $3.00, with their median price target at $2.00. Looking at these predictions, the average price target given by analysts is for Inovio Pharmaceuticals Inc. (INO) stock is $2.33.


Please enter your comment!
Please enter your name here